Results 11 to 20 of about 21,298 (206)

Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. [PDF]

Stat Med
ABSTRACT In certain settings, when conducting a randomized trial would be infeasible, electronic health records (EHR) can be used to emulate a target trial and estimate causal effects of an intervention. This process involves specifying the elements of a hypothetical trial protocol and applying these to the design of an observational study conducted ...
Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.   +4 more
europepmc   +2 more sources

Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer. [PDF]

Clin Pharmacol Ther
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Chigutsa E, Chapman SC, Turner PK.
europepmc   +2 more sources

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

BMC Cancer, 2021
Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to ...
Daniel C. Beachler, Cynthia de Luise, Aziza Jamal-Allial, Ruihua Yin, Devon H. Taylor, Ayako Suzuki, James H. Lewis, James W. Freston, Stephan Lanes   +8 more
doaj   +1 more source

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells [PDF]

, 2016
The angiogenic inducer CCN1 (Cysteine-rich 61, CYR61) is differentially activated in metastatic breast carcinomas. However, little is known about the precise mechanisms that underlie the pro-metastatic actions of CCN1. Here, we investigated the impact of
Espinoza, Ingrid, Lupu, Ruth, Menendez, Javier A., Vellón, Luciano   +3 more
core   +1 more source

Targeted Therapies for Each Subtype of Breast Cancer. [PDF]

MedComm (2020)
This review systematically summarizes the advances in targeted therapies for the three major molecular subtypes of breast cancer (BC), highlighting key strategies, agents, and clinical progress to guide personalized treatment. HR‐positive (luminal) BC: Dominated by estrogen receptor (ER) signaling, with endocrine therapies as the cornerstone—including ...
Liu A, Peng P, Zhu Y, Fei Q, Liu W, Zhang S.   +5 more
europepmc   +2 more sources

Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways [PDF]

, 2019
The epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) control the epithelial-to-mesenchymal transition (EMT) splicing program in cancer. However, their role in breast cancer recurrence is unclear. In this study, we report that high levels
Badve, Sunil S., Goswami, Chirayu P., Gu, Xiaoping, Gu, Yuan, Gökmen‐Polar, Yesim, Janga, Sarath C., Nallamothu, Gouthami, Neelamraju, Yaseswini, Ryan, Michael, Vieth, Edyta   +9 more
core   +1 more source

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [PDF]

, 2013
IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data
Arena, Francis P, Baselga, José, Burris, Howard A, Cahana, Ayelet, Campone, Mario, Erdkamp, Frans, Feng, Wentao, Gnant, Michael, Harb, Wael A, Hortobagyi, Gabriel N, Lebwohl, David, Melichar, Bohuslav, Noguchi, Shinzaburo, Petrakova, Katarina, Piccart, Martine, Pistilli, Barbara, Pritchard, Kathleen I, Rugo, Hope S, Taran, Tetiana, Yardley, Denise A   +19 more
core   +2 more sources

Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer. [PDF]

, 2019
Whole exome sequencing (WES), targeted gene panel sequencing and single nucleotide polymorphism (SNP) arrays are increasingly used for the identification of actionable alterations that are critical to cancer care.
Carpten, John D, Kaur, Pushpinder, Lang, Julie E, Porras, Tania B, Ring, Alexander   +4 more
core   +3 more sources

Quality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

Therapeutic Advances in Medical Oncology, 2023
Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in postmenopausal women with HR+/HER2− advanced breast cancer (ABC).
Ariadna Tibau, M. Teresa Martínez, Manuel Ramos, Luis De La Cruz-Merino, Ana Santaballa, Miriam O’Connor, Noelia Martínez-Jañez, Fernando Moreno, Isaura Fernández, Juan Antonio Virizuela, Jesús Alarcón, Juan de La Haba-Rodríguez, Pedro Sánchez-Rovira, Cinta Rosa Albacar, Coralia Bueno Muiño, Catherine Kelly, Maribel Casas, Susana Bezares, Libertad Rosell, Joan Albanell   +19 more
doaj   +1 more source

Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells [PDF]

, 2017
Purpose: Early detection is essential for treatment plans before onset of metastatic disease. Our purpose was to demonstrate feasibility to detect and monitor estrogen receptor 1 (ESR1) gene mutations at the single circulating tumor cell (CTC) level in ...
Austin, Laura, Capoluongo, Ettore, Cristofanilli, Massimo, Fortina, Paolo, Knudsen, Karen E., Mu, Zhaomei, Nguyen, Thomas, Paolillo, Carmela, Rossi, Giovanna, Schiewer, Matthew J.   +9 more
core   +3 more sources